Fig. 1.
Effect of dabigatran etexilate (DE) 30 mg/kg or control on bleeding time followed by (A) Beriplex, (B) NovoSeven, (C) Factor Eight Inhibitor Bypassing Activity (FEIBA) and Octaplex, and (D) Profilnine and Bebulin. Data represent mean ± SEM (n = 5–8 animals per group). *P < 0.05 versus control. †P < 0.05 versus dabigatran alone. The vertical arrow indicates the time of administration of each coagulation factor concentrate (CFC). Bebulin (Baxter BioScience, Westlake Village, CA); Beriplex (CSL Behring, Marburg, Germany); FEIBA (Baxter AG, Vienna, Austria); NovoSeven (NovoNordisk, Bagsværd, Denmark); Octaplex (Octapharma AG, Lachen, Switzerland); Profilnine (Grifols Biologicals Inc., Los Angeles, CA).